Nicolas Iragorri1,2, Mark Hofmeister1,2, Eldon Spackman3,4, Glen S Hazlewood1,2. 1. From the Departments of Medicine and Community Health Sciences, O'Brien Institute of Public Health, and the Health Technology Assessment Unit, University of Calgary, Calgary, Alberta, Canada. 2. N. Iragorri, BSc, Health Technology Assessment Unit, Department of Community Health Sciences, Cumming School of Medicine, University of Calgary; M. Hofmeister, BSc, BN, Health Technology Assessment Unit, Department of Community Health Sciences, Cumming School of Medicine, University of Calgary; E. Spackman, PhD, Department of Community Health Sciences and O'Brien Institute for Public Health, Health Technology Assessment Unit, University of Calgary; G.S. Hazlewood, MD, PhD, Department of Medicine, Cumming School of Medicine, University of Calgary. 3. From the Departments of Medicine and Community Health Sciences, O'Brien Institute of Public Health, and the Health Technology Assessment Unit, University of Calgary, Calgary, Alberta, Canada. eldon.spackman@ucalgary.ca. 4. N. Iragorri, BSc, Health Technology Assessment Unit, Department of Community Health Sciences, Cumming School of Medicine, University of Calgary; M. Hofmeister, BSc, BN, Health Technology Assessment Unit, Department of Community Health Sciences, Cumming School of Medicine, University of Calgary; E. Spackman, PhD, Department of Community Health Sciences and O'Brien Institute for Public Health, Health Technology Assessment Unit, University of Calgary; G.S. Hazlewood, MD, PhD, Department of Medicine, Cumming School of Medicine, University of Calgary. eldon.spackman@ucalgary.ca.
Abstract
OBJECTIVE: To systematically review the effects of biologic therapies for psoriatic arthritis [secukinumab, ustekinumab, adalimumab, etanercept, certolizumab pegol (CZP), apremilast, golimumab (GOL), or infliximab (IFX)] on work productivity. METHODS: A systematic review of Medline, EMBASE, CENTRAL, and ClinicalTrials.gov was conducted to identify randomized controlled trials reporting on work productivity outcomes at the end of the placebo-controlled double-blind period. RESULTS: There were 7959 records identified. Full text of 377 records was further assessed for eligibility, of which 5 trials were included. All included trials were assessed with the Cochrane Risk of Bias Tool, and 4 out of 5 were judged to be of low risk of bias in most domains. Improvements in self-assessed work productivity were observed in 5 trials (IFX, GOL, CZP, ustekinumab, and apremilast), ranging from a mean difference of -0.9 to -1.8 on a 1-10 scale of self-assessed work productivity (negative change represents improvement), although statistical significance of the results was not reported for CZP and apremilast. Treatment with CZP resulted in a statistically significant reduction in absenteeism (200 mg) and presenteeism (200 and 400 mg). IFX and GOL reported a nonsignificant reduction of absenteeism. The Work Productivity Survey, the Work Limitations Questionnaire, and visual analog scales were used to measure work productivity. CONCLUSION: Treatment with IFX, GOL, CZP, ustekinumab, and apremilast resulted in improvements in self-reported work productivity. A pooled analysis was not possible because of the clinical heterogeneity of the trials and variability in outcome reporting.
OBJECTIVE: To systematically review the effects of biologic therapies for psoriatic arthritis [secukinumab, ustekinumab, adalimumab, etanercept, certolizumab pegol (CZP), apremilast, golimumab (GOL), or infliximab (IFX)] on work productivity. METHODS: A systematic review of Medline, EMBASE, CENTRAL, and ClinicalTrials.gov was conducted to identify randomized controlled trials reporting on work productivity outcomes at the end of the placebo-controlled double-blind period. RESULTS: There were 7959 records identified. Full text of 377 records was further assessed for eligibility, of which 5 trials were included. All included trials were assessed with the Cochrane Risk of Bias Tool, and 4 out of 5 were judged to be of low risk of bias in most domains. Improvements in self-assessed work productivity were observed in 5 trials (IFX, GOL, CZP, ustekinumab, and apremilast), ranging from a mean difference of -0.9 to -1.8 on a 1-10 scale of self-assessed work productivity (negative change represents improvement), although statistical significance of the results was not reported for CZP and apremilast. Treatment with CZP resulted in a statistically significant reduction in absenteeism (200 mg) and presenteeism (200 and 400 mg). IFX and GOL reported a nonsignificant reduction of absenteeism. The Work Productivity Survey, the Work Limitations Questionnaire, and visual analog scales were used to measure work productivity. CONCLUSION: Treatment with IFX, GOL, CZP, ustekinumab, and apremilast resulted in improvements in self-reported work productivity. A pooled analysis was not possible because of the clinical heterogeneity of the trials and variability in outcome reporting.
Entities:
Keywords:
BIOLOGICAL THERAPY; EMPLOYMENT; PRODUCTIVITY; PSORIATIC ARTHRITIS; WORK